Frequency 2%
8.000 patients

Gene name: USH1C (also known as: AIE-75, DFNB18, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C and harmonin)

Gene size: 3241 (bp)

Protein name: Harmonin

Protein size: 899 (aa)

There are 11 different transcripts known for this gene


There are currently a number of trials that may be relevant to patients with mutations in the USH1C gene:

  • Stem cell therapy jCyte
  • Stem cell therapy Cedars-Sinai
  • Natural history study USH 1C
  • Start Ataluren
  • Medicine ‘translational read-through’ therapy
  • Medicine SLO-RP and NAC-ATTACK
  • Study vestibulo-cochlear implant (VCI)


By now, Dr. Lentz and her team in Louisiana have started a natural historystudy with patients having mutations in the USH 1C gene. Both the eyesight and the loss of balance are accurately recorded.


Jennifer Lentz from New Orleans (LSU School of Medicine, USA) is working on a treatment for USH1C patients who have a specific mutation in the USH1C gene, the c.216G>A mutation.


Gwenaëlle Géléoc is assistant professor in the Boston Children’s Hospital and the Harvard Medical School. She did research into gene therapy for USH1C. The USH1C gene does the coding for the ‘harmonin’ protein. Géléoc and her colleagues applied the USH1C gene with the help of an AAV vector to mice with mutations in the USH1C gene.


In Australia, a clinical trial phase 1/2 was started with financial support from the Foundation Fighting Blindness
Nacuity Pharmaceuticals launched this trial under the name SLO-RP. The safety and effectiveness of the medicine NPI-001, an experimental antioxidant, will be tested in the coming two years. The medicine appears to be really promising for slowing down the deterioration of eyesight with people suffering from RP and Usher Syndrome, irrespective of which gene is defective or which mutations have taken place.


Westerfield and colleagues are busy testing various medicines against Parkinson’s disease and Alzheimer’s disease in their zebrafish models for Usher Syndrome. Expectations are that this will slow down the deterioration of the hearing and eyesight of the zebrafish.


In London researchers wants to start testing the drug Ataluren in patients with Retinitis Pigmentosa as a result of “nonsense” mutations in USH2a and USH1c


Nagel-Wolfrum studied read-through medicines (abbreviated by TRID = Translational Readthrough Inducing Drug), as a possible therapy for USH 1C.


jCyte, is a company that has developed retinal progenitor cells (RPCs), a type of stem cell that only retinal cells can become. Clinical studies have shown that these cells can reach and even replace diseased retinal cells. The results of a phase 1 / 2a trial have shown that the treatment is safe and does not cause an immune response.

The Los Angeles-based Cedars-Sinai company has also received approval from the FDA to initiate a phase 1 / 2a clinical trial for patients with RP.


Rod-cone therapy is independent of the gene and focused on treating the rods in the eye while keeping the cones intact. The rods of the retina die first (see light and dark).


Also investigations and studies are conducted in the world that do not specifically offer a solution for people suffering from Usher Syndrome, but that may be of significance for them in the future. Solutions, therapies and medical aids for other disorders can in a later stage be applied to people suffering from Usher Syndrome as well.


The proteins control all processes in our bodies. These proteins are built using codes that have been captured in the DNA. Due to a writing error in the DNA a protein can be produced incorrectly or not at all. Fixing this DNA error changes the production of the protein and so makes the disorder disappear or reduces the symptoms. This is the idea behind the genetic therapies that are now under development throughout the world.


There are many challenges in research into Usher syndrome. Researchers specifically focus on a methodology, a strategy and / or a specific Usher protein.